The TARGET trial is an ongoing international, phase II, open-label, single-arm study designed to assess the long-term efficacy and safety of adjuvant osimertinib administered over five years in patients with completely resected stage II to IIIB NSCLC harboring EGFR mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.